Abstract Details

Title The Impact of Telemedicine on Serious Mental Illness and Movement Disorders: A Literature Review and Gap Analysis

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-003

Objective

To report the findings of a systematic literature review and gap analysis of research on the treatment of serious mental illness (SMI) and movement disorders (MDs) through telemedicine.

Background Although telemedicine has been available for decades, the COVID-19 pandemic precipitated a rapid increase in utilization and widespread experimentation with the care model. While much has been reported about telemedicine’s ability to increase access to care, less is known about its impact on quality of care, cost of care, and health disparities, particularly for those living with SMI and MDs.

Design/Methods Literature databases were searched for peer-reviewed journal articles and conference abstracts published after January 1, 2011, focusing on telemedicine, SMI or MDs, and specified outcomes. Seven independent reviewers systematically reviewed titles and abstracts of eligible publications and extracted ten data points for analysis.

Results One hundred and twelve studies (80 journal articles; 32 conference abstracts) comprised the study network. Seventy-one (63.4%) studies measured acceptability of telemedicine and 22 (19.6%) measured utilization, while quality of care and cost of care were measured in 40 (35.7%) and 19 (17.0%) studies, respectively. Fifteen (13.4%) studies compared telemedicine head-to-head with in-person care alone. Nine (8.0%) studies evaluated, or offered commentary on, the impact of telemedicine on health disparities.

Conclusions The vast majority of study outcomes evaluated the convenience of telemedicine as compared to key metrics such as quality of care, costs, or health disparities. A very limited number of direct comparisons have been conducted assessing the impact of telemedicine versus in-person care in persons living with MDs, and even fewer in SMI. Collectively, these findings reveal a meaningful evidence gap regarding the impact of telemedicine on key outcomes for persons living with SMI and MDs. Further exploration of these outcomes is critical to understanding the effectiveness – including benefits and limitations – of telemedicine compared to in-person care.

Authors/Disclosures
Eric Jen (Neurocrine Biosciences, Inc.) PRESENTER	Eric Jen has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.
	No disclosure on file
Kendra Martello (Neurocrine Biosciences)	No disclosure on file

��ɫ��

��ɫ��